142 related articles for article (PubMed ID: 21916830)
1. Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.
Advani RH; Hong F; Horning SJ; Kahl BS; Manola J; Swinnen LJ; Habermann TM; Ganjoo K
Leuk Lymphoma; 2012 Apr; 53(4):718-20. PubMed ID: 21916830
[No Abstract] [Full Text] [Related]
2. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Stopeck AT; Unger JM; Rimsza LM; LeBlanc M; Farnsworth B; Iannone M; Glenn MJ; Fisher RI; Miller TP
Blood; 2012 Aug; 120(6):1210-7. PubMed ID: 22734071
[TBL] [Abstract][Full Text] [Related]
3. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
Micallef IN; Maurer MJ; Wiseman GA; Nikcevich DA; Kurtin PJ; Cannon MW; Perez DG; Soori GS; Link BK; Habermann TM; Witzig TE
Blood; 2011 Oct; 118(15):4053-61. PubMed ID: 21673350
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
Ganjoo K; Hong F; Horning SJ; Gascoyne RD; Natkunam Y; Swinnen LJ; Habermann TM; Kahl BS; Advani RH
Leuk Lymphoma; 2014 Apr; 55(4):768-72. PubMed ID: 23786456
[TBL] [Abstract][Full Text] [Related]
5. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Sonneveld P; Hop W; Mulder AH; Michiels JJ; Blijham G; van de Lelie J; Raemakers JW; Nieuwenhuis K; van der Heul C
Semin Hematol; 1994 Apr; 31(2 Suppl 3):9-12. PubMed ID: 8073309
[No Abstract] [Full Text] [Related]
6. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
Li L; Duan W; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Zhang X; Chang Y; Nan F; Yan J; Li Z; Young KH; Zhang M
Br J Haematol; 2017 Sep; 178(5):772-780. PubMed ID: 28597542
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
8. [Doxorubicin and etoposide-besed combination chemotherapy regimen for peripheral T-cell lymphoma].
Zheng W; Zhu J; Xie Y
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):875-6. PubMed ID: 19173838
[No Abstract] [Full Text] [Related]
9. A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas.
Liu X; Yang M; Wu M; Zheng W; Xie Y; Zhu J; Song Y; Liu W
Cancer Chemother Pharmacol; 2019 Mar; 83(3):443-449. PubMed ID: 30511217
[TBL] [Abstract][Full Text] [Related]
10. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
11. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
Gleeson M; Peckitt C; To YM; Edwards L; Oates J; Wotherspoon A; Attygalle AD; Zerizer I; Sharma B; Chua S; Begum R; Chau I; Johnson P; Ardeshna KM; Hawkes EA; Macheta MP; Collins GP; Radford J; Forbes A; Hart A; Montoto S; McKay P; Benstead K; Morley N; Kalakonda N; Hasan Y; Turner D; Cunningham D
Lancet Haematol; 2018 May; 5(5):e190-e200. PubMed ID: 29703335
[TBL] [Abstract][Full Text] [Related]
12. Images in haematology. Irreversible blindness secondary to posterior reversible encephalopathy syndrome following CHOP combination chemotherapy.
Hemmaway C; Mian A; Nagy Z
Br J Haematol; 2010 Jul; 150(2):129. PubMed ID: 20487440
[No Abstract] [Full Text] [Related]
13. [Treatment of elderly patients with non-Hodgkin's lymphoma].
Titorenko IB; Kriachok IA
Lik Sprava; 2011; (5-6):79-85. PubMed ID: 22606896
[TBL] [Abstract][Full Text] [Related]
14. A Case of Lung Involvement in Peripheral T Cell Lymphoma.
Li W; Zhang L; Huang X; Feng D; Zou X; Zhou Y
Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625353
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
16. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
[TBL] [Abstract][Full Text] [Related]
17. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Hiddemann W; Kneba M; Dreyling M; Schmitz N; Lengfelder E; Schmits R; Reiser M; Metzner B; Harder H; Hegewisch-Becker S; Fischer T; Kropff M; Reis HE; Freund M; Wörmann B; Fuchs R; Planker M; Schimke J; Eimermacher H; Trümper L; Aldaoud A; Parwaresch R; Unterhalt M
Blood; 2005 Dec; 106(12):3725-32. PubMed ID: 16123223
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results.
Ruan J; Gregory SA; Christos P; Martin P; Furman RR; Coleman M; Leonard JP
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):107-13. PubMed ID: 24373788
[TBL] [Abstract][Full Text] [Related]
19. Severe skin necrosis after rituximab-CHOP therapy.
Botden IP; Leys MB; van Houten AA; Peeters RP
Neth J Med; 2008 Nov; 66(10):448-9. PubMed ID: 19011274
[No Abstract] [Full Text] [Related]
20. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]